Oral fluoropyrimidines in the treatment of advanced colorectal cancer - Results of two consecutive phase II trials

被引：2
作者：
Adimi, P
Hansen, F
Kjaer, M
Aabo, K
Keldsen, N
Pfeiffer, P
Sandberg, E
Jakobsen, A [1 ]
机构：
[1] Vejle Hosp, Dept Oncol, DK-7100 Vejle, Denmark
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Aalborg Hosp, Aalborg, Denmark
[4] Herning Cent Hosp, Herning, Denmark
[5] Odense Univ Hosp, DK-5000 Odense, Denmark
[6] Esbjerg Cent Hosp, Esbjerg, Denmark
[7] Viborg Hosp, Dept Med, Viborg, Denmark
来源：
ACTA ONCOLOGICA | 2002年 / 41卷 / 02期
关键词：
D O I：
10.1080/028418602753669625
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：202 / 203
页数：2
相关论文
共 8 条
[1]  
CARMICHAEL J, 1999, P AN M AM SOC CLIN, V18, P1015
[2]   High-dose folinic acid and 5-fluorouracil alone or combined with hydroxyurea in advanced colorectal cancer - A randomized trial of the Italian Oncology Group for Clinical Research [J].
Di Costanzo, F ;
Gasperoni, S ;
Malacarne, P ;
Belsanti, V ;
Luppi, G ;
Marzola, M ;
Corgna, E ;
Sdrobolini, A ;
Passalacqua, R ;
Figoli, F ;
Algeri, R ;
Zironi, S ;
Angiona, S ;
Boni, C .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1998, 21 (04) :369-375
[3]   Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study [J].
Hoff, PM ;
Ansari, R ;
Batist, G ;
Cox, J ;
Kocha, W ;
Kuperminc, M ;
Maroun, J ;
Walde, D ;
Weaver, C ;
Harrison, E ;
Burger, HU ;
Osterwalder, B ;
Wang, AO ;
Wong, R .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) :2282-2292
[4]  
Jakobsen A, 2001, ACTA ONCOL, V40, P63
[5]  
PAZDUR R, 1999, ASCO, P18
[6]   A systematic overview of chemotherapy effects in colorectal cancer [J].
Ragnhammar, P ;
Hafström, L ;
Nygren, P ;
Glimelius, B .
ACTA ONCOLOGICA, 2001, 40 (2-3) :282-308
[7]   Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients [J].
Schüller, J ;
Cassidy, J ;
Dumont, E ;
Roos, B ;
Durston, S ;
Banken, L ;
Utoh, M ;
Mori, K ;
Weidekamm, E ;
Reigner, B .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2000, 45 (04) :291-297
[8]   Capecitabine (Xeloda™) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma [J].
Twelves, C ;
Boyer, M ;
Findlay, M ;
Cassidy, J ;
Weitzel, C ;
Baker, C ;
Osterwalder, B ;
Jamieson, C ;
Hieke, K .
EUROPEAN JOURNAL OF CANCER, 2001, 37 (05) :597-604
1